The world’s first FDA-cleared, computer-based platform designed expressly for primary-care physicians to measure and monitor brain health to detect the early signs of dementia.
Cognivue® Cognitive Assessment Tool Receives FDA Clearance
Cerebral Assessment Systems is excited to announce that it has received FDA clearance for its revolutionary Cognivue® cognitive assessment system—a first-of-its-kind, computer-based tool designed to better and more easily assess, measure, and monitor brain function to detect early signs of dementia.
In fact, Cognivue is so unique that it led the FDA to create an entirely new class of devices, designated “Cognitive Assessment Aids” (FDA Category: 882.1470). This clearance allows Cerebral Assessment Systems to begin production and marketing of Cognivue.
For more information on Cognivue, we invite you to read our press release.
Want to know more about Cognivue?Contact Us
Cerebral Assessment Systems in the News
The Human Spectrum
Every brain ages differently. That is why we have designed our tests to target individual brain areas to get a complete diagnosis, and work out a treatment plan that fits the patient.
CAS uses a cognitive psychophysical approach to study brain function, by engaging patients in continuous stimulus-response paradigms that demand an intervening cognitive process. This approach enables the measurement of focal cortical function to be compared to individual and group performance standards to assist clinicians in the detection and monitoring of cognitive impairment.
Want to know more about Cognivue? Join our mailing list.
Get on our list now, and we'll contact you when our technologies become available.